A systematic approach for scale-down model development and characterization of commercial cell culture processes

Biotechnology Progress

Volumn 22, Issue 3, 2006, Pages 696-703

  Li, Feng ^a   Hashimura, Yasunori ^a   Pendleton, Robert ^a   Harms, Jean ^a   Collins, Erin ^a   Lee, Brian ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOREACTORS; MATHEMATICAL MODELS; METABOLITES; PROTEINS; REGULATORY COMPLIANCE;

CELL GROWTH; COMMERCIAL PROCESS; PRODUCT QUALITY;

CELL CULTURE;

CARBON DIOXIDE; OXYGEN; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BIOREACTOR; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHO CELL; COMPARATIVE STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG EFFECT; EQUIPMENT; EQUIPMENT DESIGN; HAMSTER; INSTRUMENTATION; METHODOLOGY; MICROBIOLOGY; PH; PHYSIOLOGY; REPRODUCIBILITY; TEMPERATURE; TIME;

ANIMALS; BIOREACTORS; CARBON DIOXIDE; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; CULTURE MEDIA; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HYDROGEN-ION CONCENTRATION; INDUSTRIAL MICROBIOLOGY; MODELS, BIOLOGICAL; OXYGEN; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; TEMPERATURE; TIME FACTORS;

EID: 33745037702     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp0504041     Document Type: Article

References (14)

1. Chirino, A. J.; Mire-Sluis, A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 2004, 22, 1383-1391.
2. Seely, J. E.; Seely, R. A rational, stepwise approach to process characterization. BioPharm Int. 2003, Aug, 24-34.
3. Rathore, A. S.; Wang, A.; Menon, M.; Riske, F.; Campbell, J.; Goodrich, E.; Martin, J. Optimization, scale-up and validation issues in filtration of biopharmaceuticals-Part I. BioPharm Int. 2004, Aug.
4. Rathore, A. S.; Noferi, J. F.; Arling, E. R.; Sofer, G.; Watler, P.; O'Leary, R. Process validation how much to do and when to do it. BioPharm Int. 2002, Oct, 18-28.
5. FDA Guidance for Industry: Q5E Comparability of Biotechnological/ Biological Products Subject to Changes in Their Manufacturing Process, http://www.fda.gov/cder/guidance/index.htm, June, 2005.
6. Rathore, A.; Krishnan, R.; Tozer, S.; Smiley, D.; Rausch, S. Scaling Down of Biopharmaceutical Unit Operations Part 1: Fermentation. BioPharm Int. 2005, Mar.
7. Moran, E. B.; McGowan, S. T.; McGuire, J. M.; Frankland, J. E.; Oyebade, I. A.; Waller, W.; Archer, L. C.; Morris, L. O.; Pandya, J.; Nathan, S. R.; Smith, L.; Cadette, M. L.; Michalowski, J. T. A systematic approach to the validation of process control parameters for monoclonal antibody production in fed-batch culture of a murine myeloma. Biotechnol. Bioeng. 2000, 69 (3), 242-255.
8. Kelley, B. Establishing process robustness using designed experiments. In Pharmaceutical Process Validation; Sofer, G., Zabriskie, D., Eds.; Marcel Dekker Press: New York, 1999.
9. Chisti, Y. Animal-cell damage in sparged bioreactors. TIBTECH 2000, 18, 420-432.
10. Michaels, J. D.; Mallik, A. K.; Papoutsakis, E. T. Sparging and agitation-induced injury of cultured animal cells: Do cell-to-bubble interactions in the bulk liquid injure cells? Biotechnol. Bioeng. 1996, 51, 399-409.
11. Venkat, R. V.; Chalmers, J. J. Characterization of agitation enviroments in 250 mL spinner vessel, 3 L, and 20 L reactor vessels used for animal cell microcarrier culture. Cytotechnology 1996, 22, 95-102.
12. Marks, D. M. Equipment design considerations for large scale cell culture. Cytotechnology 2003, 42, 21-33.
13. Xie, L.; Metallo, C.; Warren, J.; Pilbrough, W.; Peltier, J.; Zhong, T.; Pikus, L.; Yancy, A.; Leung, J.; Aunins, J. G.; Zhou, W. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER. C6 cell culture under sparging conditions. Biotechnol. Bioeng. 2003, 83 (1), 45-52.
14. 2 removal in large-scale fed-batch cultures. Biotechnol. Prog. 2003, 19 (1), 45-51.